Katja Wosikowski currently works for Isarna Therapeutics as director preclinical operations, where she is responsible for advancing Isarna´s 2nd generation antisense molecules into the clinic. Besides being a licensed pharmacist, she holds a doctorate in cellular biology from the University of  Basel and did a 5-year postdoctoral research stay at the National Cancer
Institute, Bethesda, USA. During her 20+ years of experience in drug discovery and development, she has been in positions with increasing responsibilities in biopharmaceutical
companies, managing and leading preclinical development projects of innovative compounds including small molecule inhibitors, antibodies and antisense molecules, as well as herbal drugs. During this time, she gathered experience in different therapeutic fields such as oncology, ophthalmology, and respiratory diseases.